NSS治疗临床T_2期肾细胞癌16例疗效分析  

Outcome of clinical stage T2renal cell carcinoma treated with nephron-sparing surgery(Report of 16 cases)

作　　者：钟明珠[1] 黄黎明[1] 罗润标 袁丹[1] 付锦高[1] 林智[1] 陈伟文[1] 

机构地区：[1]江门市中心医院,中山大学附属江门医院泌尿外科,广东江门529030

出　　处：《临床泌尿外科杂志》2015年第1期20-23,共4页Journal of Clinical Urology

摘　　要：目的：初步评价临床T2期肾细胞癌患者行保留肾单位手术（NSS）治疗的安全性及疗效。方法：回顾性分析2011年6月～2014年3月施行NSS治疗的16例临床T2期肾细胞癌患者临床资料，对这些患者的一般资料、手术时间、术中缺血时间、术中出血量、术后并发症、控瘤及肾功能保护效果等情况进行评价。结果：全部手术获得成功，手术时间（216±11）min；冷缺血时间（27±2）min；术中出血量（288±30）ml。术后无严重并发症。随访6～39个月，平均（20．9±10．9）个月，所有患者均无瘤生存，血清Cr水平上升（16．6±15．5）umol／L。结论：对临床Tz期肾细胞癌患者施行NSS技术上可行，短期临床效果良好。Objective： To evaluate the safety and efficacy of nephron-sparing surgery （NSS） in treatment of clinical stage T2 renal cell carcinoma. Method： The records of 16 patients with clinical stage T2 kidney cancer treated with NSS from June 2011 to March 2014 were reviewed. Clinical characteristics including demographics, operating time, ischemia time, intraoperative blood loss, postoperative complications, oncological and functional outcomes were analyzed. Result： The operation was successfully performed in all patients with mean operating time of （216±11） min, cold ischemia time of （27±2） min and intraoperative blood loss of （288±30） ml. No severe postoperative complications were documented. All patients were recurrence free over a mean follow-up period of （20.9 ±10.9） months （range, 6 39）. Mean serum creatinine increase was （16.6±15.5） μmol/L. Conclusion： NSS for clinical stage T2 renal cell carcinoma is technically feasible and achieves oncological and functional efficacy in the short postoperative period.

关 键 词：肾癌 肾切除术 保留肾单位手术 

分 类 号：R737.11[医药卫生—肿瘤]